Opinion|Videos|August 7, 2024

EMBARK Study: ADT in Nonmetastatic Castration-Sensitive Prostate Cancer

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME